about
Vascular and plaque imaging with ultrasmall superparamagnetic particles of iron oxideOptical coherence tomography versus intravascular ultrasound to evaluate stent implantation in patients with calcific coronary artery diseaseTransient global amnesia as the presenting feature of heparin-induced thrombocytopenia.Therapeutic inhibition of tumour necrosis factor alpha in patients with heart failure: cooling an inflamed heart.Nanoparticle enhanced MRI scanning to detect cellular inflammation in experimental chronic renal allograft rejection.Perioperative elafin for ischaemia-reperfusion injury during coronary artery bypass graft surgery: a randomised-controlled trialHuman neutrophil elastase: mediator and therapeutic target in atherosclerosis.Ferumoxytol-enhanced magnetic resonance imaging methodology and normal values at 1.5 and 3TComputed tomography myocardial perfusion vs 15O-water positron emission tomography and fractional flow reserveRole of the endogenous elastase inhibitor, elafin, in cardiovascular injury: from epithelium to endothelium.The potential of neutrophil elastase inhibitors as anti-inflammatory therapies.A 29-year-old male with chest pain and haemoptysis.Percutaneous patent foramen ovale closure in a patient with platypnoea-orthodeoxia syndrome.Percutaneous patent foramen ovale closure in a patient with platypnoea-orthodeoxia syndrome.Management of upper gastrointestinal haemorrhage complicating dual anti-platelet therapy.Ultrasmall superparamagnetic particles of iron oxide in patients with acute myocardial infarction: early clinical experience.Guidelines for liver transplantation for patients with non-alcoholic steatohepatitisMultimodality imaging guides management of an enlarging saphenous vein graft aneurysmGene delivery of the elastase inhibitor elafin protects macrophages from neutrophil elastase-mediated impairment of apoptotic cell recognition
P50
Q26783581-BB36D002-3D32-48D5-9BBB-E61DA250A100Q28603491-B11DE909-9F47-485A-9D5E-CD38E0DB9381Q33388459-ECF16023-63F7-40CD-BD5B-7C4B95B5506FQ35026157-E381B18B-157B-4857-A0FD-5BEE7392E5D6Q35543722-FF4AC4D8-BE10-4783-8C6E-011C2E4E58A6Q36209021-5E23B481-5122-43EA-A134-BAD439BA3A89Q37090805-DA10BAA4-0B10-4E52-AF1E-117D3E06F03AQ37133482-AAF67E84-4037-422D-9139-401D66E4247AQ37639667-83AE25D8-D917-4F0B-8DD1-19A153B19D46Q37958578-C14FE6C0-2DB6-4F46-A0AA-E25EA798717FQ38163381-FD9885D6-ECF8-4936-8FAA-DB4236EF946AQ40405845-E65CDD68-2442-4303-A400-514FF0B43372Q41389117-8D25E949-3AFA-4091-AA30-6A59483DB80AQ41909777-37A8C499-18AD-4DB3-B374-1B8D3664A884Q46770235-49CADBEB-15FA-4FBD-84DE-7EFF778F70E4Q53103995-C259E587-0B4C-42DA-962A-76014043E509Q64449640-A2E509C2-8FFF-4E24-9C0B-3FF158FBA9D4Q64449642-7D744CAB-DE35-4A59-A9E4-911E4E783DE5Q64449647-4CB289F7-094B-4A33-9E31-4F59BC473CBB
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Peter A Henriksen
@ast
Peter A Henriksen
@en
Peter A Henriksen
@es
Peter A Henriksen
@nl
Peter A Henriksen
@sl
type
label
Peter A Henriksen
@ast
Peter A Henriksen
@en
Peter A Henriksen
@es
Peter A Henriksen
@nl
Peter A Henriksen
@sl
prefLabel
Peter A Henriksen
@ast
Peter A Henriksen
@en
Peter A Henriksen
@es
Peter A Henriksen
@nl
Peter A Henriksen
@sl
P106
P21
P31
P496
0000-0003-4974-0344